The ARK Genomic Revolution ETF remains a "Buy" as it beats SPY/XLV, shows bullish breakout signals, and targets $42. Learn more about the fund.

Cathie Wood’s ARK ETF published their daily trades for Thursday, January 15, 2026, revealing a continued focus on Intellia Therapeutics Inc (NASDAQ:NTLA). The firm purchased a total of 56,769 shares ...

ARK Invest bought $7.27M Netflix stock and sold $4.19M Beam Therapeutics on Jan 21, 2026. Full breakdown of Cathie Wood's ...

Ark Invest, led by Cathie Wood, issued another "Big Ideas" list on Wednesday, sharing themes for 2026 that investors should ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International stock ...

In the biotech space, ARK acquired 127,184 shares of CRISPR Therapeutics AG (NASDAQ:CRSP) through its ARKK and ARKG ETFs, ...

In trading on Thursday, the iShares U.S. Home Construction ETF is outperforming other ETFs, up about 3.8% on the day. Components of that ETF showing particular strength include shares of LGI Homes, up ...

In the latest trading session, Cathie Wood's ARK ETFs continued to adjust their portfolios, with significant moves seen in both buying and selling across various sectors. The largest transaction for ...

Amid the trying circumstances in the market right now, investors may be well served to target the best biotech ETFs to buy. Fundamentally, these exchange-traded funds benefit from permanent relevance.